Jurox has launched an opioid analgesic containing buprenorphine for use in dogs, cats and horses.
Called Buprelieve, it joins Alfaxan as the latest addition to the Jurox family of products.
Buprelieve is a 0.3mg/ml buprenorphine solution for injection licensed for postoperative analgesia in all three species and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by IM or IV injection to dogs and cats, and via IV injection to horses. It is available in 10ml multi-dose glass vials for easy administration.
Jurox veterinary services manager Rich Irvine said: “We are delighted to be extending our range of products with the launch of Buprelieve, which will provide veterinary practices with effective and economical analgesia.
“The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons, who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups.”
Transparency on pricing
Jurox also claims it is responding to calls for high-quality generic medicines at affordable prices, along with transparency on what they are paying for each vial.
Jurox country manager Richard Beckwith said: “Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products.”
- For more information, contact your local Jurox technical advisor, email email@example.com or telephone the customer services team on 0800 500 3171.